title: Plasma fibrinogen in NIDDM: the Rotterdam study.
abstract: OBJECTIVE
  To compare plasma fibrinogen levels across groups of subjects with and without NIDDM with respect to diabetes therapy and to evaluate the influence of metabolic control and other selected factors.
  
  
  METHODS
  In a cross-sectional study, plasma fibrinogen was measured in 2,971 elderly subjects aged 55 years and older (mean age 70.8 years). This was part of the baseline examination of the Rotterdam Study, a population-based study of chronic diseases in the elderly.
  
  
  RESULTS
  Plasma fibrinogen levels did not differ among subjects with and without NIDDM (2.84 vs. 2.81 milligrams, P = 0.5). After adjustment for age, sex, smoking, BMI, and waist-to-hip ratio, the plasma fibrinogen levels were higher in subjects receiving insulin therapy. In those without diabetes (n = 2,640), with diabetes but not taking antidiabetes medication (n = 196), taking oral medication (n = 99), and taking insulin (n = 36), the age- and sex-adjusted fibrinogen levels were 2.82 (SE 0.01), 2.79 (0.05), 2.79 (0.07), and 3.23 (0.11) milligrams, respectively (P < 0.005). Adjustment for leukocyte count or serum creatinine level did not affect the observed association, while adjustment for fructosamine decreased the differences.
  
  
  CONCLUSIONS
  Plasma fibrinogen levels are elevated in insulin-treated NIDDM patients, which may reflect worse metabolic control in this subgroup.
authors.affiliation: Department of Epidemiology and Biostatistics, Erasmus University Medical School, Netherlands.
authors.forename: R M
authors.initials: RM
authors.lastname: Missov
authors.forename: R P
authors.initials: RP
authors.lastname: Stolk
authors.forename: J G
authors.initials: JG
authors.lastname: van der Bom
authors.forename: A
authors.initials: A
authors.lastname: Hofman
authors.forename: M L
authors.initials: ML
authors.lastname: Bots
authors.forename: H A
authors.initials: HA
authors.lastname: Pols
authors.forename: D E
authors.initials: DE
authors.lastname: Grobbee
mesh_terms: D000367:Age Factors; D000368:Aged; D015992:Body Mass Index; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005340:Fibrinogen / Q000032:analysis*; D019270:Fructosamine; D006595:Hexosamines / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D012016:Reference Values; D012727:Sex Characteristics; D012737:Sex Factors; D012907:Smoking
chemical_list: D006595:Hexosamines; D007004:Hypoglycemic Agents; D007328:Insulin; D019270:Fructosamine; D005340:Fibrinogen